EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Edgewise Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$37.92+0.73 (+1.96%)
Close on Oct 19, 2026
- Market cap
- $4.08B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
119M of 109M shares
Institutional holders
225
42 new, 26 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
1 buys · 33 sales
Net sold $19.30M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | 8,392,730 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Paradigm BioCapital Advisors LP | 6,541,210 | 6.20% | 13G (passive) amendment | Dec 31, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. | 6,395,546 | 6.10% | 13G (passive) amendment | Mar 31, 2025 |
| Janus Henderson Group PLC | 5,915,556 | 5.50% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 5,824,866 | 5.50% | 13G (passive) amendment | Jun 30, 2025 |
| FMR LLC | 5,489,135 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Joseph Edelman | 5,164,487 | 5.50% | 13G (passive) | Feb 13, 2025 |
| Orbimed Advisors LLC | 15,252,867 | 14.50% | 13D (active) amendment | May 9, 2025 |
| RA Capital Healthcare Fund, L.P. | 10,428,437 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Paradigm BioCapital Advisors GP LLC | 10,215,455 | 9.50% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EWTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 15,518,492 | 14.29% | $630.52M | – | 11.68% |
| Paradigm Biocapital Advisors LP | 10,215,455 | 9.41% | $415.05M | +2,850,417 | 7.77% |
| Ra Capital Management, L.P. | 8,392,730 | 7.73% | $341.00M | −2,035,707 | 2.96% |
| BlackRock, Inc. | 6,606,336 | 6.08% | $268.42M | +133,345 | 0.00% |
| Jupiter Topco LLC | 6,075,331 | 5.59% | $246.95M | New | 0.10% |
| FMR LLC | 5,489,135 | 5.05% | $223.02M | +4,472,083 | 0.01% |
| Novo Holdings A/S | 5,350,000 | 4.93% | $217.37M | – | 12.62% |
| Driehaus Capital Management LLC | 4,728,623 | 4.35% | $192.12M | +250,681 | 1.11% |
| Perceptive Advisors LLC | 4,373,974 | 4.03% | $177.71M | −50,000 | 2.67% |
| Vanguard Capital Management LLC | 3,860,670 | 3.55% | $156.86M | +72,509 | 0.00% |
| Baker Bros. Advisors LP | 3,701,719 | 3.41% | $150.40M | −2,874,221 | 0.75% |
| Siren, L.L.C. | 3,184,629 | 2.93% | $129.39M | −1,245,634 | 2.62% |
| Cormorant Asset Management, LP | 2,510,000 | 2.31% | $101.98M | −750,000 | 5.23% |
| Geode Capital Management, LLC | 2,174,051 | 2.00% | $88.35M | +384,232 | 0.00% |
| Alliancebernstein L.P. | 2,119,024 | 1.95% | $66.75M | +396,855 | 0.02% |
| Integral Health Asset Management, LLC | 2,000,000 | 1.84% | $81.26M | +400,000 | 3.21% |
| Braidwell LP | 1,996,965 | 1.84% | $81.14M | −350,618 | 3.00% |
| Morgan Stanley | 1,948,597 | 1.79% | $79.17M | −297,431 | 0.00% |
| State Street Corp | 1,827,927 | 1.68% | $74.27M | +111,104 | 0.00% |
| Mpm Bioimpact LLC | 1,620,780 | 1.49% | $65.85M | −39,916 | 4.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 225 | 119M | 100.0% | 42 / 83 | 73 / 26 | 22M | 15M |
| Q1 2026 | 214 | 119M | 100.0% | 44 / 66 | 65 / 25 | 12M | 10M |
| Q4 2025 | 199 | 122M | 100.0% | 48 / 69 | 54 / 20 | 18M | 7M |
| Q3 2025 | 173 | 112M | 100.0% | 18 / 59 | 61 / 23 | 4M | 11M |
| Q2 2025 | 178 | 119M | 100.0% | 30 / 88 | 39 / 41 | 22M | 9M |
| Q1 2025 | 192 | 106M | 97.3% | 33 / 70 | 60 / 38 | 14M | 7M |
| Q4 2024 | 200 | 99M | 91.2% | 44 / 70 | 64 / 20 | 10M | 12M |
| Q3 2024 | 177 | 102M | 93.5% | 53 / 57 | 45 / 15 | 21M | 15M |
| Q2 2024 | 140 | 102M | 93.7% | 33 / 59 | 30 / 21 | 16M | 7M |
| Q1 2024 | 129 | 92M | 85.1% | 32 / 60 | 28 / 19 | 33M | 21M |
| Q4 2023 | 116 | 80M | 73.6% | 38 / 44 | 19 / 7 | 13M | 1M |
| Q3 2023 | 85 | 68M | 63.0% | 9 / 41 | 17 / 18 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EWTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,902,230 | 2.67% | $117.92M | 0.01% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,940,531 | 1.79% | $66.29M | 0.03% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,835,831 | 1.69% | $74.59M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 864,638 | 0.80% | $35.13M | 0.04% | Jun 30, 2026 |
| Small Cap Growth Fund | 856,214 | 0.79% | $32.90M | 0.59% | Jul 31, 2026 |
| Victory Pioneer Select Mid Cap Growth Fund | 795,789 | 0.73% | $27.18M | 1.43% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 782,053 | 0.72% | $30.05M | 0.09% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 699,425 | 0.64% | $23.89M | 0.45% | May 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 677,076 | 0.62% | $27.51M | 0.47% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 660,219 | 0.61% | $26.82M | 0.17% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 642,530 | 0.59% | $24.69M | 0.28% | Jul 31, 2026 |
| iShares Biotechnology ETF | 556,093 | 0.51% | $22.59M | 0.25% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 533,585 | 0.49% | $21.68M | 0.69% | Jun 30, 2026 |
| Driehaus Small Cap Growth Fund | 522,169 | 0.48% | $21.22M | 1.32% | Jun 30, 2026 |
| Ab Discovery Growth Fund, Inc. | 489,862 | 0.45% | $19.90M | 0.69% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alan J. Russell | Chief Scientific Officer, Director | 31,856 | 0.03% | Aug 17, 2026 |
| Kevin Koch | President and CEO, Director | 391,272 | 0.36% | Aug 14, 2026 |
| Behrad Derakhshan | Chief Business Officer | 29,426 | 0.03% | Aug 17, 2026 |
| John R. Moore | General Counsel | 15,995 | 0.01% | Aug 17, 2026 |
| Joanne M. Donovan | CMO | 8,625 | 0.01% | Aug 17, 2026 |
| Michael Nofi | Chief Financial Officer | – | – | Aug 17, 2026 |
| Robert Blaustein | Chief Development Officer | – | – | Aug 14, 2025 |
| R. Michael Carruthers | Chief Financial Officer | 86,162 | 0.08% | Aug 14, 2025 |
| Marc Semigran | Chief Development Officer | 6,716 | 0.01% | Dec 27, 2024 |
| Jonathan D. Root | Director | 15,625 | 0.01% | Jul 17, 2026 |
| Jonathan C. Fox | Director | 24,833 | 0.02% | Jul 1, 2026 |
| Arlene Morris | Director | – | – | Jun 17, 2026 |
| Laura Brege | Director | – | – | Jun 17, 2026 |
| Peter A. Thompson | Director, 10% owner | 443,792 | 0.41% | Jun 17, 2026 |
| Badreddin Edris | Director | 96,760 | 0.09% | Jun 16, 2026 |
| Christopher Nathan Martin | Director | – | – | Jun 16, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 319,599 | 0.29% | Apr 4, 2025 |
| Capital GP VI LLC OrbiMed | Director, 10% owner | 14,436,497 | 13.29% | Apr 4, 2025 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 14,809,075 | 13.64% | Apr 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joanne M. Donovan CMO | Aug 13, 2026 | Sale(10b5-1 plan) | −2,919 | $43.41 | $126.71K | 8,625 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Option exercise | +5,781 | – | – | 29,426 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Option exercise | +7,500 | – | – | 36,926 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −2,171 | $43.79 | $95.07K | 34,755 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −304 | $44.50 | $13.53K | 34,451 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −2,475 | $43.70 | $108.16K | 31,826 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −150 | $44.44 | $6.67K | 34,301 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Sale | −913 | $44.33 | $40.47K | 52,488 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Option exercise | +17,969 | – | – | 48,584 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Option exercise | +21,875 | – | – | 70,459 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Sale | −8,782 | $43.64 | $383.25K | 61,677 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Sale | −8,276 | $43.66 | $361.33K | 53,401 |
| John R. Moore General Counsel | Aug 12, 2026 | Option exercise | +5,781 | – | – | 15,995 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −2,419 | $43.80 | $105.95K | 17,697 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −99 | $44.50 | $4.41K | 20,116 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −59 | $44.41 | $2.62K | 20,215 |
| John R. Moore General Counsel | Aug 12, 2026 | Option exercise | +6,718 | – | – | 22,713 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −2,439 | $43.81 | $106.85K | 20,274 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Sale | −2,273 | $43.68 | $99.28K | 31,856 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Sale | −390 | $44.46 | $17.34K | 31,466 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Option exercise | +5,781 | – | – | 30,336 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Option exercise | +7,031 | – | – | 37,367 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Sale | −3,238 | $43.68 | $141.44K | 34,129 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Option exercise | +5,781 | – | – | 11,035 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Option exercise | +7,031 | – | – | 18,066 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −2,839 | $43.78 | $124.29K | 15,227 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −2,779 | $43.71 | $121.47K | 12,448 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −104 | $44.43 | $4.62K | 12,344 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −800 | $44.52 | $35.62K | 11,544 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −130,352 | $39.41 | $5.14M | 94,203 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Option exercise | +130,352 | $0.45 | $58.66K | 154,907 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Option exercise | +69,648 | $0.18 | $12.54K | 224,555 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −69,648 | $39.41 | $2.74M | 24,555 |
| Jonathan C. Fox Director | Jul 1, 2026 | Award | +319 | – | – | 24,833 |
| Joanne M. Donovan CMO | May 5, 2026 | Option exercise | +50,000 | $7.08 | $354.00K | 54,367 |
| Joanne M. Donovan CMO | May 5, 2026 | Sale(10b5-1 plan) | −50,000 | $38.57 | $1.93M | 4,367 |
| Joanne M. Donovan CMO | May 4, 2026 | Sale(10b5-1 plan) | −5,230 | $31.29 | $163.65K | 4,367 |
| Jonathan C. Fox Director | Apr 1, 2026 | Award | +339 | – | – | 24,514 |
| Joanne M. Donovan CMO | Apr 1, 2026 | Sale(10b5-1 plan) | −28,662 | $32.31 | $926.07K | 9,597 |
| Joanne M. Donovan CMO | Apr 1, 2026 | Option exercise | +28,662 | $7.08 | $202.93K | 38,259 |
| Joanne M. Donovan CMO | Mar 31, 2026 | Option exercise | +21,338 | $7.08 | $151.07K | 30,935 |
| Joanne M. Donovan CMO | Mar 31, 2026 | Sale(10b5-1 plan) | −21,338 | $32.12 | $685.38K | 9,597 |
| Joanne M. Donovan CMO | Mar 27, 2026 | Sale(10b5-1 plan) | −6,735 | $30.98 | $208.65K | 9,597 |
| Joanne M. Donovan CMO | Mar 27, 2026 | Sale(10b5-1 plan) | −9,623 | $30.98 | $298.12K | 16,332 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −7,605 | $29.44 | $223.89K | 96,760 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −17,236 | $29.44 | $507.43K | 104,365 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −10,463 | $29.44 | $308.03K | 86,297 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −66,477 | $29.44 | $1.96M | 19,820 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +66,477 | $1.93 | $128.30K | 127,686 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +13,690 | $0.39 | $5.34K | 33,510 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +17,236 | $0.64 | $11.03K | 50,746 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +10,463 | $1.93 | $20.19K | 61,209 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +7,605 | $0.71 | $5.40K | 135,291 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −13,690 | $29.44 | $403.03K | 121,601 |
| Jonathan C. Fox Director | Jan 2, 2026 | Award | +473 | – | – | 24,175 |
| Alan J. Russell Chief Scientific Officer, Director | Nov 12, 2025 | Option exercise | +100,000 | $0.18 | $18.00K | 123,400 |
| Alan J. Russell Chief Scientific Officer, Director | Nov 12, 2025 | Sale | −100,000 | $21.12 | $2.11M | 23,400 |
| Jonathan C. Fox Director | Nov 11, 2025 | Buy | +10,700 | $18.64 | $199.45K | 23,702 |
| Jonathan C. Fox Director | Oct 1, 2025 | Award | +728 | – | – | 13,002 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 26, 2025 | Option exercise | +100,000 | $0.18 | $18.00K | 123,400 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Donovan Joanne Officer | Aug 13, 2026 | 2,919 | $127.15K | Aug 13, 2026 | Restricted Stock Units |
| J. Russell Alan Director, Officer | Jul 1, 2026 | 200,000 | $8.13M | Jul 1, 2026 | Exercise of Stock Options |
| Donovan Joanne Officer | May 5, 2026 | 50,000 | $1.57M | May 5, 2026 | Exercise of Stock Options |
| Donovan Joanne Officer | Mar 27, 2026 | 71,588 | $2.27M | Mar 27, 2026 | Exercise of Stock Options |
| Edris Badreddin Director | Jan 21, 2026 | 115,471 | $3.35M | Jan 21, 2026 | Stock Option Exercise |
| Michael Carruthers Robert Officer | Jan 20, 2026 | 183,867 | $5.17M | Jan 20, 2026 | Exercise of options under a registered plan |
| Michael Carruthers Robert Officer | Jan 15, 2026 | 180,872 | $4.80M | Jan 15, 2026 | Exercise of options under a registered plan |
| Michael Carruthers Robert Officer | Dec 29, 2025 | 116,665 | $3.04M | Dec 26, 2025 | Exercise of options under a registered plan |
| Michael Carruthers Robert Officer | Nov 17, 2025 | 70,000 | $1.57M | Nov 17, 2025 | Previously Exercised Options |
| J. Russell Alan Officer, Director | Nov 12, 2025 | 100,000 | $2.11M | Nov 12, 2025 | Exercise of options under a registered plan |
| J. Russell Alan Officer, Director | Aug 26, 2025 | 100,000 | $1.46M | Aug 26, 2025 | Exercise of options under a registered plan |
| Derakhshan Behrad Officer | Feb 5, 2025 | 40,000 | $1.19M | Feb 5, 2025 | NQ Stock Option Exercise |
| Koch Kevin Director, Officer | Feb 5, 2025 | 51,181 | $1.51M | Feb 5, 2025 | Exercise of Stock Options |
| J. Russell Alan Director, Officer | Feb 5, 2025 | 100,000 | $2.95M | Feb 5, 2025 | Exercise of Stock Options |
| Donovan Joanne Officer | Jan 28, 2025 | 25,000 | $696.25K | Jan 28, 2025 | Exercise of Stock Options |